Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has appointed Michael Halstead as its new chief executive officer, effective immediately, as the clinical-stage company advances its lead candidate HLP003 through Phase 3 development and prepares for potential commercialization. The announcement comes at a critical juncture, with enrollment complete in the Phase 3 APPROACH trial and topline data expected in Q4 2026.
Halstead brings 25 years of biopharmaceutical leadership experience, most recently serving as president of Intra-Cellular Therapies, where he oversaw the development and commercialization of CAPLYTA, a treatment for bipolar depression and other mental health conditions. He also supported pipeline expansion and helped lead the company's $14.6 billion acquisition by Johnson & Johnson in 2025. His appointment signals a strategic move by Helus Pharma to leverage his commercial expertise as it moves toward a potential market launch.
The company is also continuing enrollment in the EMBRACE pivotal study for HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder. Additionally, Helus Pharma is advancing HLP004, a proprietary NSA for generalized anxiety disorder, currently in Phase 2 clinical development.
Helus Pharma, the commercial operating name of Cybin Inc., focuses on developing novel serotonergic agonists (NSAs) designed to activate serotonin pathways that promote neuroplasticity. The company aims to address the large unmet need for patients with depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape by introducing therapies that provide durable improvements in mental health.
The appointment of Halstead is a pivotal step for Helus Pharma as it transitions from a clinical-stage company to one preparing for commercialization. His track record in bringing CAPLYTA to market and scaling commercial operations is expected to be instrumental in guiding HLP003 through regulatory approval and eventual launch. The company's focus on novel mechanisms of action and its pipeline of investigational NSAs could position it as a significant player in the mental health treatment market.
For investors and industry observers, Halstead's leadership may signal increased confidence in the company's prospects. The progress of HLP003 and HLP004, along with the new CEO's experience, could influence the company's trajectory in the competitive biopharmaceutical landscape. As the company advances its clinical programs, the next few years will be crucial in determining whether its innovative approach to mental health treatments can translate into successful commercialization.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's newsroom at https://nnw.fm/HELP.
